Life Sciences

  • July 08, 2026

    Sheppard Adds Transactional, IP Attys In Chicago And San Diego

    Sheppard announced Wednesday that the firm has added an experienced intellectual property attorney focused on life sciences as a San Diego area-based partner, a day after announcing the addition of two Chicago-based transactional partners.

  • July 08, 2026

    Handa, Intas Face Patent Suits Over Exelixis Cancer Drug

    Handa Pharmaceuticals and Intas Pharmaceuticals are wrongly trying to bring to market drugs that would compete with Exelixis Inc.'s blockbuster cancer pill Cabometyx before patents on the medication expire, according to a new lawsuit in Delaware federal court.

  • July 08, 2026

    Biggest Rulings For Patent Attys In 2026: A Midyear Report

    The U.S. Supreme Court clarified the pleading standard for induced infringement of skinny labels, and the Federal Circuit opened the door to increased damages for patent owners. Here's what you need to know about these patent cases and other major decisions from the beginning of 2026.

  • July 07, 2026

    2 Ex-Telehealth Execs Sentenced For $100M Adderall Scheme

    A California federal judge on Tuesday sentenced two former executives of a telehealth company who were convicted of operating a $100 million scheme to illegally distribute Adderall over the internet, fining them $1 million each and giving the founder six years in prison.

  • July 07, 2026

    Illinois Cases To Watch In 2026: Midyear Report

    Mead Johnson is set to go to trial this summer in the first case to make it to a jury in multidistrict litigation claiming baby formula caused a serious gut illness in premature infants, while the U.S. attorney's office in Chicago is facing a possible sanctions hearing over prosecutorial misconduct allegations in two Illinois cases on attorneys' radar for the rest of the year.

  • July 07, 2026

    Regeneron Ducks Amgen's Eylea Antitrust Counterclaims

    A West Virginia federal judge dismissed key counterclaims and defenses Tuesday that Amgen had raised against Regeneron's patent infringement lawsuit targeting bids by multiple would-be rivals to produce biosimilar versions of eye medication Eylea, preserving only arguments that Regeneron waited too long to pursue the patent.

  • July 07, 2026

    CEO Cops To Conspiracy In BigLaw Insider Trading Case

    A Dubai-based CEO and trader has pled guilty in Massachusetts federal court to charges that he worked with a former BigLaw associate and others to carry out a far-reaching insider trading scheme.

  • July 07, 2026

    Align's Invisalign Patents Are Infringed But Invalid, Jury Finds

    A Texas federal jury has found that claims in four patents Invisalign maker Align Technology Inc. asserted against orthodontics company ClearCorrect were invalid, but the jurors also rejected ClearCorrect's antitrust claims against Align.

  • July 07, 2026

    Unstable Ex-Pfizer Office Spurs Evacuations In Manhattan

    The reported instability of pharmaceutical giant Pfizer's former New York City office headquarters, which is undergoing a conversion into residential units, led to the evacuations of multiple nearby buildings in Midtown Manhattan Tuesday.

  • July 07, 2026

    23andMe's $47M Data Breach Deal Gets Bankruptcy Court OK

    A Missouri bankruptcy judge entered an order Tuesday authorizing a $46.7 million settlement between the plan administration trust created under the Chapter 11 plan of DNA-testing company 23andMe and data breach claimants, finding the deal is fair and equitable. 

  • July 07, 2026

    Mayo Sacked Research Director For Flagging Flaws, Suit Says

    Mayo Clinic retaliated against and eventually terminated its director of research operations after she brought up concerns about security, safety and privacy regarding the medical center's use of artificial intelligence and other protocols, according to a lawsuit filed in Minnesota federal court on Monday.

  • July 07, 2026

    P&G Brushes Off Harm Of Toothpaste Ingredient, Suit Claims

    Procter & Gamble misleads consumers of its Crest Pro-Health toothpastes by failing to convey that the ingredient sodium lauryl sulfate can damage gum and mouth tissue and trigger inflammation — "the very conditions" the products are marketed as mitigating, a proposed class action alleges in California federal court.

  • July 07, 2026

    Groups Tell 4th Circ. Not To Let Sandoz 'Relitigate' Enbrel

    Pharmaceutical groups and the Washington Legal Foundation backed Amgen in amicus briefs Monday urging the Fourth Circuit not to revive Sandoz's antitrust claims, arguing that if Sandoz wanted to litigate blocked biosimilar competition to Enbrel, it needed to do so when Amgen sued it for patent infringement.

  • July 07, 2026

    5th Circ. Again Nixes Challenge To La. 340B Drug Delivery Law

    A Fifth Circuit panel doubled down on its decision to uphold a Louisiana law prohibiting drug manufacturers from blocking contracts between pharmacies and providers in the federal 340B drug discount program, reiterating that conclusion upon rehearing but this time allowing intervention by an advocacy group.

  • July 07, 2026

    Fed. Circ. Won't Revive Dental Patent Claims In Align Feud

    The Federal Circuit on Tuesday said it won't bring back claims in a pair of dental arch image analysis patents their owner accused Invisalign maker Align Technology Inc. of infringing, backing a lower court's finding that they were invalid.

  • July 07, 2026

    Longtime Goodwin Procter IP Lawyer Moves To Pillsbury In DC

    A career Goodwin Procter LLP lawyer, who spent nearly two decades at that firm working on high-stakes intellectual property disputes, has joined Pillsbury Winthrop Shaw Pittman LLP's Washington, D.C., office.

  • July 06, 2026

    CVS To Pay $36.5M To Settle States' Insulin FCA Suits

    CVS has agreed to shell out $36.5 million to put to rest a handful of False Claims Act suits from states and the federal government, which allege the pharmacy chain submitted fraudulent Medicaid claims after giving patients more insulin than they were prescribed and lying about refill timelines.

  • July 06, 2026

    3 Firms Guide Vertex's $10B Buy Of Crinetics Pharmaceuticals

    Kirkland & Ellis LLP is advising Vertex Pharmaceuticals Inc. in its $10 billion acquisition of Crinetics Pharmaceuticals Inc., which is being represented by both Paul Weiss Rifkind Wharton & Garrison LLP and Morrison Foerster LLP, according to an announcement made Monday.

  • July 06, 2026

    5,000 Pharmacies Accuse Prime Therapeutics Of Price-Fixing

    Nearly 5,000 pharmacies accuse Prime Therapeutics LLC of entering into an unlawful price-fixing agreement with rival pharmacy benefit manager Express Scripts Inc. to deflate pharmacies' reimbursement rates and inflate their fees, according to a new lawsuit filed in Seattle federal court.

  • July 06, 2026

    Medtronic Denied Bid To Nix $382M Antitrust Loss

    A California federal court has denied Medtronic Inc.'s attempt to ditch a roughly $382 million trial loss in an antitrust case accusing the company of maintaining its monopoly over a surgical device through contracts that a jury found blocked competition.

  • July 06, 2026

    Clarivate Sells Life Sciences And Healthcare Biz For $600M

    Analytics company Clarivate PLC on Monday announced that it has agreed to sell its Life Sciences & Healthcare segment to investment firm Altaris LLC in a $600 million deal built by three law firms.

  • July 06, 2026

    Latest Squires Order Accepts 9 Patent Petitions, Rejects 2

    The U.S. Patent and Trademark Office director granted nine petitions for America Invents Act patent scrutiny and denied two others, while also saying he'd assess the merits of a dozen other challenges.

  • July 06, 2026

    3M, Chubb Settle Suit Over Warming Device Defense Coverage

    3M Co. and Chubb unit Federal Insurance Co. reached a deal resolving a dispute over insurance coverage for thousands of product liability lawsuits claiming that a 3M post-surgery warming device caused patients to develop infections.

  • July 06, 2026

    DOJ Urges DC Circ. Not To Freeze Medical Pot Rescheduling

    The U.S. Department of Justice has urged the D.C. Circuit not to grant a request to freeze a final rule rescheduling medical marijuana while opponents challenge the policy in a case in which various industry stakeholders are wrangling to participate.

  • July 06, 2026

    NC Biz Court Bulletin: Rapid-Fire Rulings, Word Of Warning

    Summer is heating up in North Carolina Business Court with a slew of recent rulings, including one greenlighting a data breach class action brought by current and former workers who allege Charlotte-based Bojangles failed to guard their personal information from hackers.

Expert Analysis

  • USPTO Initiatives May Bolster SEP Litigation In The US

    Author Photo

    The U.S. Patent and Trademark Office's recent efforts to revitalize standard-essential patent litigation face hurdles in their reliance on courts and other agencies, but may help the U.S. regain its central role in global SEP litigation if successful, say attorneys at Axinn.

  • Series

    Trail Running Makes Me A Better Lawyer

    Author Photo

    Navigating the muddy, root-filled path of trail marathons and ultramarathons provides fertile training ground for my high-stakes fractional general counsel work, teaching me to slow down my mind when the terrain shifts, sharpen my focus and trust my training, says Eric Proos at Next Era Legal.

  • Predicting Actual Impact From CDC's New Vaccine Guidance

    Author Photo

    Recent federal changes to the childhood immunization schedule, reducing the number of vaccine recommendations from 18 to 11, do not automatically create enforceable obligations for parents, schools or healthcare providers, but may spur litigation and other downstream effects on school policies and state guidelines, says Mehdi Sinaki at Michelman & Robinson.

  • AI Scientific Discovery Order Implications For Life Sciences

    Author Photo

    President Donald Trump's November executive order establishing a government effort to use artificial intelligence to accelerate scientific discovery has the potential to leverage significant federal resources and data to support research, drug and device approvals, and AI model training in the life sciences sector, say attorneys at Hogan Lovells.

  • What Rescheduling Means For Cannabis Labels, Marketing

    Author Photo

    The proposed reclassification of cannabis is expected to bring heightened scrutiny of labeling, advertising and marketing from the U.S. Food and Drug Administration and the Federal Trade Commission, but the brands that tighten evidence, standardize operations and professionalize marketing controls now will see fewer surprises and better outcomes, say attorneys at Wilson Elser.

  • Tips From Del. Decision Nixing Major Earnout Damages Award

    Author Photo

    The Delaware Supreme Court recently vacated in part the largest earnout-related damages award in Delaware history, making clear that the implied covenant of good faith and fair dealing cannot be used to rescue parties from drafting choices where the relevant regulatory risk was foreseeable at signing, say attorneys at Sullivan & Cromwell.

  • USPTO's New Patentability Focus Helps Emerging Tech

    Author Photo

    The U.S. Patent and Trademark Office's recent efforts to shift patentability criteria back toward traditional standards of novelty, obviousness and adequate disclosure should make it easier for emerging tech, including artificial intelligence, to obtain patents, says Bill Braunlin at Barclay Damon.

  • Malpractice Claim Assignability Continues To Divide Courts

    Author Photo

    Recent decisions from courts across the country demonstrate how different jurisdictions balance competing policy interests in determining whether legal malpractice claims can be assigned, providing a framework to identify when and how to challenge any attempted assignment, says Christopher Blazejewski at Sherin & Lodgen.

  • Courts' Rare Quash Of DOJ Subpoenas Has Lessons For Cos.

    Author Photo

    In a rare move, three federal courts recently quashed or partially quashed expansive U.S. Department of Justice administrative subpoenas issued to providers of gender-affirming care, demonstrating that courts will scrutinize purpose, cabin statutory authority and acknowledge the profound privacy burdens of overbroad government demands for sensitive records, say attorneys at ArentFox Schiff.

  • Unpacking Dormant Commerce Clause Cannabis Circuit Split

    Author Photo

    Federal courts have reached differing conclusions as to whether state-legal cannabis is subject to the dormant commerce clause, with four opinions across three circuit courts in the last year demonstrating the continued salience of the dormant commerce clause debate to the nation's cannabis industry, regulators and policymakers, say attorneys at Perkins Coie.

  • Opinion

    CFIUS Must Adapt To Current Foreign Investment Realities

    Author Photo

    To continue protecting the U.S.’ long-term strategic and economic interests, the Committee on Foreign Investment in the United States should implement practical enhancements that leverage technology, expertise and clear communication, and enable it to keep pace with evolving demands, says attorney Sohan Dasgupta.

  • Utah's AI Prescription Renewal Pilot Could Inform Policy

    Author Photo

    Utah recently became the first state to approve an artificial intelligence system for autonomously renewing certain prescription medicines, providing a test case for how regulators may be able to draw boundaries between administrative automation and medical judgment, say Jashaswi Ghosh at Holon Law Partners and Bryant Godfrey at Foley Hoag.

  • Ramped Up Psychedelic Production Carries Opportunity, Risk

    Author Photo

    Kimberly Chew at Husch Blackwell discusses the key legal implications of the U.S. Drug Enforcement Administration's recent dramatic increases in the production quotas for a range of psychedelic substances, offering guidance on compliance, risk management and strategic opportunities for practitioners navigating this rapidly evolving landscape.

  • Series

    Teaching Logic Makes Me A Better Lawyer

    Author Photo

    Teaching middle and high school students the skills to untangle complicated arguments and identify faulty reasoning has made me reacquaint myself with the defined structure of thought, reminding me why logic should remain foundational in the practice of law, says Tom Barrow at Woods Rogers.

  • New Biotech Nat'l Security Controls May Have Blunted Impact

    Author Photo

    While the newly enacted federal prohibition against contracting with certain biotechnology providers associated with countries of concern may have consequences on U.S. companies' ability to develop drugs, the restrictions may prove to be less problematic for the industry than the significant publicity around their passage would suggest, say attorneys at Wilson Sonsini.

Want to publish in Law360?


Submit an idea

Have a news tip?


Contact us here
Can't find the article you're looking for? Click here to search the Life Sciences archive.